Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Entera Bio Ltd.NASDAQ: ENTX
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 39.2% from a year ago
Total assets stood at $13.13M at the end of Q1 FY2026, down 39.2% from a year earlier and down 17.9% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -39.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 15.99M USD
- Year-over-year change
- +70.3%
- 4-year CAGR
- -11.4%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.99M | +70.3% |
| FY2024 | 2024-12-31 | 9.39M | -20.2% |
| FY2023 | 2023-12-31 | 11.77M | -10.4% |
| FY2022 | 2022-12-31 | 13.13M | -49.5% |
| FY2021 | 2021-12-31 | 25.99M | — |
Total Assets vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total assets of $13.13M is the lowest of the 10 companies compared; the peer median is $66.79M.
- Its year-over-year change of -39.2% is the 9th highest of 10, against a peer median of -21.6%.
- Over three fiscal years its annual growth of +6.8% compares with a peer median of -18.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $272.13M | -21.6% | -15.3% | |
| Mar 2026 | $186.46M | -6.9% | -18.1% | |
| Mar 2026 | $133.63M | -34.6% | -14.5% | |
| Mar 2026 | $117.62M | -28.4% | -26.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $66.79M | +38.7% | +0.8% |
| Mar 2026 | $59.02M | -24.0% | -18.0% | |
| Mar 2026 | $49.78M | -43.0% | -40.3% | |
| Mar 2026 | $29.7M | +102.9% | +21.6% | |
| Apr 2026 | $14.87M | -12.4% | -19.1% | |
| Mar 2026 | $13.13M | -39.2% | +6.8% | |
| Peer median (excluding ENTX) | $66.79M | -21.6% | -18.0% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.